1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Drug News 11 MAY 2015

Cancer Drug News 11 MAY 2015

  • May 2015
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Diversification To Bolster Celgene's Revenues
Industry Brief - Roche's Venetoclax Gains FDA Breakthrough Therapy Designation
Industry Trend Analysis - Zykadia Will Not Surpass Xalkori Without First-Line Approval
Industry Brief - ESSA's IND Application For EPI-506 Placed On Clinical Hold By FDA
Industry Brief - FDA Grants ODD To Oncolytics' Reolysin For Gastric Cancers
Industry Brief - Baxter Seeks EU Approval For MM-398 In Post-Gemcitabine MPC
Industry Brief - Can-Fite's CF102 Phase II HCC Trial Approved In Europe
Industry Trend Analysis - CytRx' Outperformance To Continue
Industry Brief - Plexxikon/Merck Collaborate On PLX3397/Keytruda Combination Trial
Industry Brief - COT Granted European Patent Covering COTI-2
Industry Brief - Qu Biologics Granted EU Patent Covering Use Of Bacterial Compositions In Cancer
Industry Brief - Acacia Reports Positive Results From Phase II Study With APD403 In CINV
Industry Brief - FDA Grants Fast Track Designation To Sucampo's Cobiprostone
Industry Trend Analysis - EpiTherapeutics Acquisition Will Be Start Of Oncology Deals For Gilead In 2015

Table Of Contents

Cancer Drug News 11 MAY 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Hematological Malignancies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Hematological Malignancies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

Hematological Malignancies Market: Overview This report provides in-depth region wise and country wise analysis of the hematological malignancies market. Stakeholders of this report include manufacturers ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.